90-Day Mortality After Emergency Department Discharge in Advanced Cancer

NCT07167095 | Completed

• 1 other identifier: AEŞH-BADEK2-2025-242
• Study Type: observational
• Target: 1,250
• Locations: 1 country
• Sites: 1

Brief Summary

This retrospective observational study investigates factors associated with 90-day mortality among patients with advanced cancer who present to the emergency department (ED). The study will include stage IV solid tumor patients who visited the ED of Etlik City Hospital between December 2022 and March 2025. Demographic, clinical, and laboratory parameters such as performance status, nutritional and inflammatory markers, and biochemical values will be analyzed. The primary objective is to identify prognostic indicators that predict short-term mortality following ED visits. By establishing risk profiles, the study aims to optimize patient triage, guide timely referral to supportive and palliative care services, and improve overall care strategies for advanced cancer patients in acute settings.

Conditions

Advanced Cancer; Mortality; Oncology; Emergency Department Admission; Metastatic Solid Tumors

Keywords

90-Day Mortality; Emergency Department; Prognostic Factors; Performance Status; Nutritional and Inflammatory Markers; Oncology Supportive Care; Palliative Care

Outcome Measures

Primary Outcomes (1)

• 90-Day All-Cause Mortality After Emergency Department Visit

  All-cause mortality within 90 days following presentation to the emergency department among patients with stage IV solid tumors. Mortality status will be confirmed using the hospital information system (HBYS) and the national death registry (e-Nabız). Both in-hospital and out-of-hospital deaths will be included.

  90 days after emergency department visit

Secondary Outcomes (9)

• In-Hospital Mortality During Emergency Department Visit

  30 days after ED discharge

• 30-Day Emergency Department Re-admission

  30 days after ED discharge

• 90-Day Hospital Re-admission Rate

  90 days after ED discharge

• Correlation between ECOG Performance Status and 90-Day Mortality

  90 days after ED visit

• Correlation between Body Mass Index (BMI) and 90-Day Mortality

  90 days after ED visit

Study Arms (1)

Advanced Cancer Patients Presenting to the Emergency Department

This retrospective cohort includes adult patients (≥18 years) with pathologically confirmed stage IV solid tumors who presented to the emergency department of Etlik City Hospital between December 2022 and March 2025. Patients were eligible if they had received systemic anticancer therapy within the previous 6 months and had complete clinical and laboratory records. Both patients discharged from the ED and those who were admitted or died during the ED visit are included. Data collected include demographic characteristics, performance status, primary tumor type, metastatic sites, reasons for ED admission, laboratory values, and subsequent outcomes. The cohort will be analyzed to identify prognostic factors associated with 90-day mortality, ED re-admissions, and re-hospitalizations.

Other: Retrospective Data Collection and Analysis

Interventions

Retrospective Data Collection and Analysis OTHER

This intervention refers to retrospective evaluation of clinical and laboratory data of advanced cancer patients who presented to the emergency department between December 2022 and March 2025. Data will be extracted from the hospital information system (HBYS) and national death registry (e-Nabız). Parameters include demographics, ECOG performance status, primary tumor type, metastatic sites, laboratory markers (e.g., NLR, CRP, albumin, LDH), and outcomes such as 90-day mortality, re-admissions, and re-hospitalizations. No experimental treatment, drug, or device is administered as part of the study.

Also known as: Observational Chart Review

Advanced Cancer Patients Presenting to the Emergency Department

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients (aged 18 years and older) with stage IV solid tumors who presented to the emergency department of Etlik City Hospital (Ankara, Türkiye) between December 2022 and March 2025. Eligible patients must have received systemic anticancer therapy within the preceding 6 months. Both patients discharged from the ED and those who were hospitalized or who died during their ED visit are included. The estimated enrollment is 1,250 patients.

You may qualify if:

• Age ≥18 years
• Pathologically confirmed stage IV (metastatic) solid malignancy
• Followed at Etlik City Hospital, Department of Medical Oncology
• Presented to the emergency department between December 2022 and March 2025
• Either discharged on the same day, admitted to the hospital, or died during the ED visit
• Received systemic anticancer therapy (chemotherapy, immunotherapy, targeted therapy, or hormonal therapy) within the past 6 months
• Availability of complete clinical and laboratory data

You may not qualify if:

• Stage I-III cancer patients
• Patients not receiving systemic therapy, only palliative/supportive care
• Patients followed in other oncology centers but presenting to Etlik City Hospital ED
• Patients with hematologic malignancies (e.g., leukemia, lymphoma, multiple myeloma)
• Patients with missing clinical or laboratory data

Sponsors & Collaborators

• Ankara Etlik City Hospital: lead

Study Sites (1)

Ankara Etlik City Hospital

Ankara, Yenimahalle, 06210, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Neoplasms; Emergencies

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Oncologist

Study Record Dates

• First Submitted: August 24, 2025
• First Posted: September 11, 2025
• Study Start: December 1, 2022
• Primary Completion: January 1, 2023
• Study Completion: March 1, 2025
• Last Updated: September 11, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)